Overview

Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia

Status:
Completed

Trial end date:
2017-10-25

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to fludarabine-cyclophosphamide in patients with relapsed Chronic Lymphocytic Leukemia (CLL).

Phase:

Phase 3

Details

Lead Sponsor:

Novartis
Novartis Pharmaceuticals

Treatments:

Antibodies, Monoclonal
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Vidarabine